MX2023004593A - Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. - Google Patents

Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.

Info

Publication number
MX2023004593A
MX2023004593A MX2023004593A MX2023004593A MX2023004593A MX 2023004593 A MX2023004593 A MX 2023004593A MX 2023004593 A MX2023004593 A MX 2023004593A MX 2023004593 A MX2023004593 A MX 2023004593A MX 2023004593 A MX2023004593 A MX 2023004593A
Authority
MX
Mexico
Prior art keywords
tyk2
tyk2 inhibitors
inhibitors
inhibition
compositions
Prior art date
Application number
MX2023004593A
Other languages
English (en)
Inventor
Craig E Masse
Jeremy Robert Greenwood
Sayan Mondal
Scott D Cowen
Thomas H Mclean
Original Assignee
Takeda Pharmaceuticals Company Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Company Ltd filed Critical Takeda Pharmaceuticals Company Ltd
Publication of MX2023004593A publication Critical patent/MX2023004593A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente invención proporciona compuestos, composiciones de los mismos, y métodos de uso de los mismos para la inhibición de TYK2, y el tratamiento de trastornos mediados por TYK2.
MX2023004593A 2017-07-28 2020-01-28 Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos. MX2023004593A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762538536P 2017-07-28 2017-07-28
US201762560615P 2017-09-19 2017-09-19
US201862664048P 2018-04-27 2018-04-27

Publications (1)

Publication Number Publication Date
MX2023004593A true MX2023004593A (es) 2023-05-08

Family

ID=65040855

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020001103A MX2020001103A (es) 2017-07-28 2018-07-26 Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
MX2023004593A MX2023004593A (es) 2017-07-28 2020-01-28 Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2020001103A MX2020001103A (es) 2017-07-28 2018-07-26 Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.

Country Status (12)

Country Link
US (8) US11046698B2 (es)
EP (1) EP3658557A4 (es)
JP (2) JP7216705B2 (es)
KR (1) KR20200035293A (es)
CN (3) CN117946115A (es)
AU (2) AU2018306444B2 (es)
BR (1) BR112020001714A2 (es)
CA (1) CA3070621A1 (es)
IL (1) IL271999A (es)
MX (2) MX2020001103A (es)
SG (1) SG11202000714QA (es)
WO (1) WO2019023468A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3262049B1 (en) 2015-02-27 2022-07-20 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
JP7082120B2 (ja) 2016-10-21 2022-06-07 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
TW201940483A (zh) 2018-03-12 2019-10-16 美商艾伯維有限公司 酪胺酸激酶２介導的傳訊之抑制劑
CN112638915B (zh) * 2018-09-10 2023-04-07 伊莱利利公司 用于治疗银屑病和***性红斑狼疮的吡唑并[1,5-a]嘧啶-3-甲酰胺衍生物
WO2020081508A1 (en) 2018-10-15 2020-04-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
AU2019370200A1 (en) 2018-10-30 2021-06-10 Kronos Bio, Inc. Compounds, compositions, and methods for modulating CDK9 activity
SG11202108619SA (en) * 2019-02-07 2021-09-29 Ventyx Biosciences Inc Tyk2 pseudokinase ligands
JP2022529311A (ja) * 2019-03-26 2022-06-21 ベンティックス バイオサイエンシーズ，インク． Ｔｙｋ２偽キナーゼリガンド
MX2022005563A (es) * 2019-11-08 2022-08-19 Ventyx Biosciences Inc Ligandos de la pseudoquinasa tyk2.
WO2021162944A1 (en) * 2020-02-12 2021-08-19 Eli Lilly And Company Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives
AR121251A1 (es) * 2020-02-12 2022-05-04 Lilly Co Eli Compuestos de 7-(metilamino)pirazolo[1,5-a]pirimidina-3-carboxamida
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
EP4281458A1 (en) * 2021-01-19 2023-11-29 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Imidazolopyridazine or pyrazolopyrimidine compounds and compositions
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法
WO2023055901A2 (en) 2021-09-30 2023-04-06 Bristol-Myers Squibb Company Methods for determining responsiveness to tyk2 inhibitors
CA3236262A1 (en) 2021-10-25 2023-05-04 Isaac Marx Tyk2 degraders and uses thereof
WO2023183910A1 (en) * 2022-03-25 2023-09-28 Nimbus Lakshmi, Inc. Solid forms of tyk2 inhibitors and methods of use
WO2023183900A1 (en) * 2022-03-25 2023-09-28 Nimbus Lakshmi, Inc. Tyk2 inhibitor formulations and methods of making the same
WO2023183901A1 (en) * 2022-03-25 2023-09-28 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2023183908A1 (en) * 2022-03-25 2023-09-28 Nimbus Lakshmi, Inc. Tyk2 inhibitor synthesis and intermediates thereof
CN115057820A (zh) * 2022-08-04 2022-09-16 东莞理工学院 一种以乙酰丙酸合成4,5-二氢-6-甲基哒嗪-3(2h)-酮的方法

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
DE4310970A1 (de) 1993-04-03 1994-10-06 Huels Chemische Werke Ag Farblose und transparente, amorph zu verarbeitende Polyamidformmassen mit guter Spannungsrißbeständigkeit und Schlagzähigkeit
EE05351B1 (et) 1999-12-10 2010-10-15 Pfizer Products Inc. Prrolo[2,3-d]primidiinhendid
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
CA2445395C (en) 2001-04-27 2010-03-30 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent comprising the same as effective component
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
SI1536827T1 (sl) 2002-08-14 2009-06-30 Silence Therapeutics Ag Uporaba protein-kinaze n beta
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7205308B2 (en) * 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
NZ539163A (en) 2002-09-04 2007-03-30 Schering Corp Pyrazolo[1,5-a]pyrimidine compounds useful as cyclin dependent kinase (CDK) inhibitors
BRPI0314001B8 (pt) 2002-09-04 2021-05-25 Merck Sharp & Dohme pirazolopirimidinas como inibidores de cinase dependente de ciclina e composição farmacêutica compreendendo as mesmas
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
EP1599482A4 (en) 2003-02-28 2008-10-01 Teijin Pharma Ltd PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
GB0304665D0 (en) * 2003-02-28 2003-04-02 Teijin Ltd Compounds
WO2004087707A1 (en) 2003-03-31 2004-10-14 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
JP2006523237A (ja) 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ， インコーポレイテッド Ｐｉ−３キナーゼインヒビタープロドラッグ
KR101168441B1 (ko) 2003-05-30 2012-07-25 게민 엑스 파마슈티컬스 캐나다 인코포레이티드 암 또는 바이러스 질환의 치료를 위한 삼복소환 화합물,조성물 및 방법
AU2004257167B2 (en) 2003-07-03 2012-03-29 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
BRPI0414238A (pt) 2003-09-09 2006-10-31 Ono Pharmaceutical Co antagonistas de crf e compostos heterobicìclicos
DE102004008807A1 (de) * 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
PL3153514T3 (pl) 2004-05-13 2022-01-10 Icos Corporation Chinazolinony jako inhibitory ludzkiej 3-kinazy fosfatydyloinozytolowej delta
JP2006160628A (ja) 2004-12-03 2006-06-22 Ishihara Sangyo Kaisha Ltd アデノシンＡ２ａ受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物
BRPI0606318B8 (pt) 2005-01-19 2021-05-25 Rigel Pharmaceuticals Inc composto, composição, e, uso de um composto
DE102005007534A1 (de) 2005-02-17 2006-08-31 Bayer Cropscience Ag Pyrazolopyrimidine
CN101175738B (zh) 2005-05-12 2010-10-27 雅培制药有限公司 细胞凋亡促进剂
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
AR056206A1 (es) 2005-10-06 2007-09-26 Schering Corp Pirazolpirimidinas como inhibidores de protein quinasas
JP5152922B2 (ja) 2005-10-06 2013-02-27 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼを阻害するためのピラゾロ［１，５−ａ］ピリミジン誘導体の使用およびプロテインキナーゼを阻害する方法
DK1931645T3 (da) 2005-10-07 2014-09-29 Exelixis Inc N-(3-aminoquinoxalin-2-yl)-sulfonamidderivater og deres anvendelse som inhibitorer af phosphatidylinositol-3-kinase
BR122021011787B1 (pt) 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
DK2455382T3 (da) 2005-12-13 2017-01-02 Incyte Holdings Corp Heteroaryl substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus kinase-inhibitorer
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
DE602007007323D1 (de) 2006-04-26 2010-08-05 Hoffmann La Roche Thienoä3,2-düpyrimidin-derivat geeignet als pi3k inhibitor
KR101315610B1 (ko) 2006-09-22 2013-10-10 파마시클릭스, 인코포레이티드 브루톤 티로신 키나제 억제제
CA2670083A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
WO2008109178A1 (en) 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a squaramide moiety
KR101737753B1 (ko) 2007-03-12 2017-05-18 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
EA017218B1 (ru) 2008-03-11 2012-10-30 Инсайт Корпорейшн Производные азетидина и циклобутана как ингибиторы jak-киназ
US8518931B2 (en) 2008-04-07 2013-08-27 Irm Llc Compounds and compositions as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
EP2962566A1 (en) 2008-10-31 2016-01-06 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CA2773854A1 (en) 2009-09-11 2011-03-17 Cylene Pharmaceuticals Inc. Pharmaceutically useful heterocycle-substituted lactams
CA2782684C (en) 2009-12-04 2018-09-04 Mustapha Haddach Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
US20110207736A1 (en) 2009-12-23 2011-08-25 Gatekeeper Pharmaceuticals, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
KR101541086B1 (ko) 2010-08-20 2015-08-03 허치슨 메디파르마 리미티드 피롤로피리미딘 화합물 및 그 용도
KR101931224B1 (ko) * 2010-12-08 2018-12-20 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 글루코세레브로시다제 활성제로서 치환된 피라졸로피리미딘
WO2012170827A2 (en) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
WO2013052263A2 (en) 2011-09-16 2013-04-11 Microbiotix, Inc. Antifungal compounds
CA2866143C (en) 2012-03-09 2020-08-04 Lexicon Pharmaceuticals, Inc. Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
MX2015005272A (es) 2012-11-08 2015-07-14 Squibb Bristol Myers Co Compuestos de piridilo sustituidos con alquilamida utiles como moduladores de las respuestas de interleucina 12 (il-12), interleucina 23 (il-23) y/o interferon alfa (ifnalfa).
NZ707432A (en) 2012-11-16 2020-01-31 Univ Health Network Pyrazolopyrimidine compounds
EP3418281B1 (en) 2012-12-07 2020-09-30 Vertex Pharmaceuticals Inc. Pyrazolo[1,5-a]pyrimidines useful as inhibitors of atr kinase for the treatment of cancer diseases
WO2014143242A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
ES2702126T3 (es) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
GB201403093D0 (en) 2014-02-21 2014-04-09 Cancer Rec Tech Ltd Therapeutic compounds and their use
JP6526065B2 (ja) 2014-02-28 2019-06-05 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
WO2015154022A1 (en) 2014-04-05 2015-10-08 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
EP3262049B1 (en) 2015-02-27 2022-07-20 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
ES2899196T3 (es) 2015-03-09 2022-03-10 Aurigene Discovery Tech Ltd Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK
US10329294B2 (en) 2015-03-12 2019-06-25 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of IRAK4 activity
WO2017002120A1 (en) 2015-07-02 2017-01-05 Yeda Research And Development Co. Ltd. Selective inhibitors of senescent cells and uses thereof
US20180208605A1 (en) * 2015-07-15 2018-07-26 Aurigene Discovery Technologies Limited Substituted Aza Compounds as IRAK-4 Inhibitors
EP4327809A3 (en) 2015-09-02 2024-04-17 Takeda Pharmaceutical Company Limited Tyk2 inhibitors and uses thereof
US20170116285A1 (en) 2015-10-27 2017-04-27 Microsoft Technology Licensing, Llc Semantic Location Layer For User-Related Activity
ES2828733T3 (es) 2015-11-18 2021-05-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
ES2930198T3 (es) 2016-10-14 2022-12-07 Nimbus Lakshmi Inc Inhibidores de TYK2 y usos de los mismos
JP7082120B2 (ja) 2016-10-21 2022-06-07 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用
EP4338802A2 (en) 2017-03-08 2024-03-20 Takeda Pharmaceutical Company Limited Tyk2 inhibitors, uses, and methods for production thereof

Also Published As

Publication number Publication date
US10508120B2 (en) 2019-12-17
US20190241577A1 (en) 2019-08-08
JP7216705B2 (ja) 2023-02-02
BR112020001714A2 (pt) 2020-07-21
JP2023052540A (ja) 2023-04-11
CN117946114A (zh) 2024-04-30
CN111194317A (zh) 2020-05-22
US20190031664A1 (en) 2019-01-31
EP3658557A4 (en) 2020-12-09
RU2020102476A3 (es) 2021-12-10
SG11202000714QA (en) 2020-02-27
US10570145B2 (en) 2020-02-25
RU2020102476A (ru) 2021-08-30
US20190241576A1 (en) 2019-08-08
US11046698B2 (en) 2021-06-29
MX2020001103A (es) 2020-08-17
JP2020528909A (ja) 2020-10-01
AU2022279375A1 (en) 2023-01-19
US20190256519A1 (en) 2019-08-22
AU2018306444A1 (en) 2020-02-06
WO2019023468A1 (en) 2019-01-31
US20220356184A1 (en) 2022-11-10
US20190241575A1 (en) 2019-08-08
US20190248797A1 (en) 2019-08-15
KR20200035293A (ko) 2020-04-02
US10562906B2 (en) 2020-02-18
EP3658557A1 (en) 2020-06-03
AU2018306444B2 (en) 2022-11-17
US20230056447A1 (en) 2023-02-23
IL271999A (en) 2020-02-27
TW201920178A (zh) 2019-06-01
CA3070621A1 (en) 2019-01-31
US10577373B2 (en) 2020-03-03
CN117946115A (zh) 2024-04-30
US10562907B2 (en) 2020-02-18

Similar Documents

Publication Publication Date Title
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
EP3848370A3 (en) Tyk2 inhibitors and uses thereof
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
EP4327809A3 (en) Tyk2 inhibitors and uses thereof
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2019012431A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2020006812A (es) Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
MX2018006632A (es) Inhibidores biciclicos de peptidilarginina deiminasa 4 (pad4).
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2017012738A (es) Inhibidores de indolamina 2.3-dioxigenasa (ido) para el tratamiento de cancer.
EA033163B1 (ru) Ингибиторы глутаминазы
MX2021004245A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2020001793A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
MX2020013630A (es) Analogos de rapamicina y usos de los mismos.